WASHINGTON — The Trump administration had planned for insurers to provide weight loss drugs to seniors in a Medicare pilot program. Insurers said no, so the government will instead cover the drugs outside of the Medicare Part D drug benefit.
Last year, the Trump administration struck a deal with Eli Lilly and Novo Nordisk to lower the prices of their popular obesity drugs in exchange for expanding access to those drugs in Medicare and Medicaid. Medicare is prohibited from covering weight loss drugs, but the administration proposed waiving that restriction to test whether covering the medications would save tmoney or improve health outcomes at no additional cost.
The hitch was that insurers had to agree to participate in the pilot, called BALANCE , even though they would likely have faced a financial drain from doing so. The drugmakers agreed to sell the treatments for $245 a month in Medicare and Medicaid, but Medicare promised that  beneficiaries would only pay $50 each month.  Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 21 Apr 2026.
The item focuses on STAT+: Insurers refuse to join Medicare pilot offering weight loss drugs to seniors at steep discount.
Review the original article for the full source wording and details.